GlassScriptPhysician profile
Ashton C Brinson
NPI 1164499414
$8,900.75
in general payments reported to CMS, 2019-2025
49 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $1,269 · 2021: $1,055 · 2022: $1,090 · 2023: $1,394 · 2024: $2,186 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,652.42 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,414.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,042.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $868.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $609.64 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Glaxosmithkline, LLC. | $497.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $468.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.68 | 2019-2023 | Xifaxan |
| Antares Pharma, INC. | $348.85 | 2019-2025 | Xyosted |
| Allergan, INC. | $338.66 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $335.27 | 2024 | Voquezna |
| Exact Sciences Corporation | $199.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $184.21 | 2024 | Veozah |
| Abbott Laboratories | $172.41 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.78 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $133.14 | 2023-2024 | Quviviq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Brinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.